Journal Information
Vol. 95. Issue 5.
Pages 662-664 (01 September 2020)
Visits
4373
Vol. 95. Issue 5.
Pages 662-664 (01 September 2020)
Case Letter
Open Access
Malignant melanoma after treatment for Merkel cell carcinoma
Visits
4373
Masato Ishikawa
Corresponding author
ishimasa@fmu.ac.jp

Corresponding author.
, Toshiyuki Yamamoto
Department of Dermatology, Fukushima Medical University, Fukushima, Japan
This item has received

Under a Creative Commons license
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (3)
Show moreShow less
Full Text
Dear Editor,

A 98-year-old male was referred complaining of a mass on his left cheek. He had never received immunosuppressive therapy. Physical examination showed a solid, dome-shaped, reddish tumor, 35 mm in diameter, on his left cheek. Microscopic examination of a biopsy specimen revealed an infiltrative tumor in the dermis. The tumor was composed of sheets and trabeculae of atypical cells with scant cytoplasm, and round nuclei with stippled chromatin (Fig. 1). Immunohistochemistry results revealed that the tumor cells stained positive for cytokeratin 20 and neuron specific enolase. The patient underwent total resection of the tumor. However, because of the patient’s advanced age, neither the patient nor his family wished further treatment, including radiotherapy, choosing follow-up visits only. Two years later, he presented again with erosion of the right hallux. Physical examination showed widespread erosion of his right hallux, which in part had a reddish nodule. The nail had completely disappeared (Fig. 2). Histological examination revealed many atypical cells infiltrating irregularly from the epidermis to the dermis (Fig. 3). These atypical cells were immunoreactive for MART-1 and HMB-45. For the same reason as before, the patient and his family wanted only local symptomatic treatments at a nearby hospital.

Figure 1.

Microscopic examination of a biopsy specimen from a mass on patient’s left cheek. There was an infiltrative tumor in the dermis. The tumor was composed of sheets and trabeculae of atypical cells with scant cytoplasm, and round nuclei with stippled chromatin (Hematoxylin & eosin, ×200).

(0.21MB).
Figure 2.

Physical examination revealed widespread erosion of the right hallux, which in part had a reddish nodule. The nail had completely disappeared.

(0.09MB).
Figure 3.

Histological examination showed many atypical cells infiltrating irregularly from the epidermis to the dermis (Hematoxylin & eosin, ×200).

(0.15MB).

Merkel cell carcinoma (MCC) is a rare cutaneous neuroendocrine cancer that is known to be a highly aggressive malignancy with frequent metastasis and a high mortality rate. A previous review article revealed increased risk of a second primary cancer after the diagnosis of MCC, and cutaneous malignant melanoma (MM) is one of the most common cancers after MCC.1 Miller and Rabkin reported that occurrences of MM and MCC were similarly increased with sun exposure and immunosuppression.2 Considering that ultra violet (UV) rays attenuate systemic immune responses via the induction of regulatory T-cells, systemic immunosuppression may be an essential factor in the development of both conditions in a patient.3 In the present case, MCC occurred on the left cheek, and MM occurred on the right hallux. In Japan, the majority of MM cases occur on the edges of limbs that are not directly affected by UV rays, and external irritation has been considered one of the risk factors.4 However, systemic immunosuppression associated with aging and/or UV irradiation may be a common cause of both conditions in the present case. According to previous articles, several cases in which MCC and MM developed in a patient have been reported from countries other than Japan; however, to the best of the authors’ knowledge, this is the first report of its type from Japan. Interestingly, there was a report of a case of MCC that developed in a patient during treatment with immune checkpoint inhibitors for MM.2,5 Given the increase of immune checkpoint inhibitors used to treat MM, the number of cases in which both MCC and MM develop in a patient may increase in Japan, as well as around the world.

Financial support

None declared.

Authors' contributions

Masato Ishikawa: Drafting and editing of the manuscript; collection, analysis, and interpretation of data; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the literature.

Toshiyuki Yamamoto: Approval of the final version of the manuscript; conception and planning of the study; critical review of the manuscript.

Conflicts of interest

None declared.

References
[1]
A. Saxena, M. Rubens, V. Ramamoorthy, H. Khan.
Risk of second cancers in Merkel cell carcinoma: a meta-analysis of population based cohort studies.
J Skin Cancer., 2014 (2014),
[2]
R.W. Miller, C.S. Rabkin.
Merkel cell carcinoma and melanoma etiological similarities and differences.
Cancer Epidemiol Biomarkers Prev., 8 (1999), pp. 153-158
[3]
S.V. Milliken, H. Wassall, B.J. Lewis, J. Logie, R.N. Barker, H. Macdonald, et al.
Effects of ultraviolet light on human serum 25-hydroxyvitamin D and systemic immune function.
J Allergy Clin Immunol., 129 (2012), pp. 1554-1561
[4]
K. Ishihara, T. Saida, F. Otsuka, N. Yamazaki.
Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society. Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update.
Int J Clin Oncol, 13 (2008), pp. 33-41
[5]
T. Hajar, E.E. Hill, J.J. Leitenberger.
Development of Merkel cell carcinoma and squamous cell carcinoma during treatment with pembrolizumab for metastatic mucosal melanoma.
Dermatol Surg., 1 (2019),

How to cite this article: Ishikawa M, Yamamoto T. Malignant melanoma after treatment for Merkel cell carcinoma. An Bras Dermatol. 2020; 95. https://doi.org/10.1016/j.abd.2020.02.013.

Study conducted at the Fukushima Medical University, Fukushima, Japan.

Copyright © 2020. Sociedade Brasileira de Dermatologia
Idiomas
Anais Brasileiros de Dermatologia
Article options
Tools
en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.